# A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

> **NCT02562508** · PHASE3 · COMPLETED · sponsor: **Jun Zhang** · enrollment: 979 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia
- Cervical Cancer
- Vaginal Intraepithelial Neoplasia
- Vulvar Intraepithelial Neoplasia
- Persistent Infection

## Interventions

- **PROCEDURE:** 3 doses of HPV 16/18 bivalent vaccine
- **PROCEDURE:** 2 doses of HPV 16/18 bivalent vaccine

## Key facts

- **NCT ID:** NCT02562508
- **Lead sponsor:** Jun Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-05
- **Primary completion:** 2016-08-12
- **Final completion:** 2016-08-12
- **Target enrollment:** 979 (ACTUAL)
- **Last updated:** 2018-08-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02562508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02562508, "A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02562508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*